A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland
Tekijät: Mononen N, Ikonen T, Syrjakoski K, Matikainen M, Schleutker J, Tammela TLJ, Koivisto PA, Kallioniemi OP
Kustantaja: CHURCHILL LIVINGSTONE
Julkaisuvuosi: 2001
Journal: British Journal of Cancer
Tietokannassa oleva lehden nimi: BRITISH JOURNAL OF CANCER
Lehden akronyymi: BRIT J CANCER
Vuosikerta: 84
Numero: 10
Aloitussivu: 1344
Lopetussivu: 1347
Sivujen määrä: 4
ISSN: 0007-0920
DOI: https://doi.org/10.1054/bjoc.2001.1789
Tiivistelmä
Prostatic steroid 5-alpha-reductase gene (SRD5A2) encodes a critical enzyme involved in the conversion of testosterone to dihydrotestosterone. A germline mis-sense substitution (A49T) leads to a variant SRD5A2 protein, which has a 5-fold higher in vitro V-max than the wild-type protein (Ross et al, 1998; Makridakis et al. 1999). The A49T variant was recently associated with 2.5 to 3.28-fold increased risk of prostate cancer (PC) in African-American and Hispanic men (Makridakis et al, 1999). Also, Jaffe et at (2000) reported an association between A49T and more aggressive disease among Caucasian patients. Here, we report that the prevalence of the A49T variant in 449 Finnish PC patients was 6.0%, not significantly different from 6.3% observed in 223 patients with benign prostatic hyperplasia or 5.8% in 588 population-based controls (odds ratio for PC 1.04, 95% C.I. 0.62-1.76, P = 0.89). There was no association between A49T and the family history of the patients nor with tumour stage or grade. Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population. (C) 2001 Cancer Research Campaign.
Prostatic steroid 5-alpha-reductase gene (SRD5A2) encodes a critical enzyme involved in the conversion of testosterone to dihydrotestosterone. A germline mis-sense substitution (A49T) leads to a variant SRD5A2 protein, which has a 5-fold higher in vitro V-max than the wild-type protein (Ross et al, 1998; Makridakis et al. 1999). The A49T variant was recently associated with 2.5 to 3.28-fold increased risk of prostate cancer (PC) in African-American and Hispanic men (Makridakis et al, 1999). Also, Jaffe et at (2000) reported an association between A49T and more aggressive disease among Caucasian patients. Here, we report that the prevalence of the A49T variant in 449 Finnish PC patients was 6.0%, not significantly different from 6.3% observed in 223 patients with benign prostatic hyperplasia or 5.8% in 588 population-based controls (odds ratio for PC 1.04, 95% C.I. 0.62-1.76, P = 0.89). There was no association between A49T and the family history of the patients nor with tumour stage or grade. Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population. (C) 2001 Cancer Research Campaign.
Turun yliopiston Tutkimustietojärjestelmän portaali